Literature DB >> 21528487

Inhibitory activities of microalgal extracts against Epstein-Barr virus DNA release from lymphoblastoid cells.

Yih-Yih Kok1, Wan-Loy Chu, Siew-Moi Phang, Shar Mariam Mohamed, Rakesh Naidu, Pey-Jiun Lai, Shui-Nyuk Ling, Joon-Wah Mak, Patricia Kim-Chooi Lim, Pauline Balraj, Alan Soo-Beng Khoo.   

Abstract

This study aimed to assess the inhibitory activities of methanol extracts from the microalgae Ankistrodesmus convolutus, Synechococcus elongatus, and Spirulina platensis against Epstein-Barr virus (EBV) in three Burkitt's lymphoma (BL) cell lines, namely Akata, B95-8, and P3HR-1. The antiviral activity was assessed by quantifying the cell-free EBV DNA using real-time polymerase chain reaction (PCR) technique. The methanol extracts from Ankistrodesmus convolutus and Synechococcus elongatus displayed low cytotoxicity and potent effect in reducing cell-free EBV DNA (EC(50)<0.01 µg/ml) with a high therapeutic index (>28000). After fractionation by column chromatography, the fraction from Synechococcus elongatus (SEF1) reduced the cell-free EBV DNA most effectively (EC(50)=2.9 µg/ml, therapeutic index>69). Upon further fractionation by high performance liquid chromatography (HPLC), the sub-fraction SEF1'a was most active in reducing the cell-free EBV DNA (EC(50)=1.38 µg/ml, therapeutic index>14.5). This study suggests that microalgae could be a potential source of antiviral compounds that can be used against EBV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21528487      PMCID: PMC3087089          DOI: 10.1631/jzus.B1000336

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  24 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.

Authors:  Y M Lo; L Y Chan; K W Lo; S F Leung; J Zhang; A T Chan; J C Lee; N M Hjelm; P J Johnson; D P Huang
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

3.  Possible anti-tumor promoting properties of marine algae and in vivo activity of Wakame seaweed extract.

Authors:  H Ohigashi; Y Sakai; K Yamaguchi; I Umezaki; K Koshimizu
Journal:  Biosci Biotechnol Biochem       Date:  1992-06       Impact factor: 2.043

Review 4.  Epstein-Barr viral gene expression in B-lymphocytes.

Authors:  F Schwarzmann; M Jäger; M Hornef; N Prang; H Wolf
Journal:  Leuk Lymphoma       Date:  1998-06

Review 5.  Epstein-Barr virus infections: prospects for treatment.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Antimicrob Chemother       Date:  2005-07-08       Impact factor: 5.790

6.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

7.  Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Authors:  Masanori Daibata; Kentaro Bandobashi; Masayuki Kuroda; Shosuke Imai; Isao Miyoshi; Hirokuni Taguchi
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Acerogenin M, a cyclic diarylheptanoid, and other phenolic compounds from Acer nikoense and their anti-inflammatory and anti-tumor-promoting effects.

Authors:  Toshihiro Akihisa; Yosuke Taguchi; Ken Yasukawa; Harukuni Tokuda; Hiroyuki Akazawa; Takashi Suzuki; Yumiko Kimura
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-05       Impact factor: 1.645

9.  Pathogenic role of Epstein-Barr virus in human cancer.

Authors:  K Takada; N Shimizu; A Tanabe-Tochikura; Y Kuroiwa
Journal:  Intervirology       Date:  1995       Impact factor: 1.763

10.  Carrageenan is a potent inhibitor of papillomavirus infection.

Authors:  Christopher B Buck; Cynthia D Thompson; Jeffrey N Roberts; Martin Müller; Douglas R Lowy; John T Schiller
Journal:  PLoS Pathog       Date:  2006-07       Impact factor: 6.823

View more
  2 in total

1.  Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.

Authors:  Léna Petit; Léa Vernès; Jean-Paul Cadoret
Journal:  J Appl Phycol       Date:  2021-03-20       Impact factor: 3.215

2.  Allelopathy as a potential strategy to improve microalgae cultivation.

Authors:  Leonardo Brantes Bacellar Mendes; Alane Beatriz Vermelho
Journal:  Biotechnol Biofuels       Date:  2013-10-21       Impact factor: 6.040

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.